Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

GTX-104

Other · developed by Grace Therapeutics

Phase 3 Most advanced trial
GRCE Developer
1 Registered trials

What is GTX-104?

GTX-104 is a drug studied in aneurysmal subarachnoid hemorrhage (aSAH), a form of bleeding around the brain caused by a ruptured aneurysm.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Neurology
Developer
Grace Therapeutics Inc. (GRCE)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05995405 Phase 3 Aneurysmal Subarachnoid Hemorrhage (aSAH) Active not recruiting GRCE

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Aneurysmal Subarachnoid Hemorrhage (aSAH)

More from Grace Therapeutics

GTX-101 Phase 1

Follow GRCE, the company behind GTX-104

See GRCE's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

GRCE catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.